Jeffrey S. Aronin
| Jeff Aronin | |
|---|---|
| Born | December 8, 1967 |
| Education | BA (Marketing) 1989 |
| Alma mater | Northern Illinois University |
| Occupation | CEO and founder of Marathon Pharmaceuticals LLC |
Jeff Aronin (born December 8, 1967) is a biopharmaceutical executive. He is chairman, CEO, and founder of Marathon Pharmaceuticals LLC, a privately owned company headquartered in Northbrook, Illinois. He is also chairman, CEO and founder of Paragon Pharmaceutical Capital, LLC, an investment firm that backs healthcare companies.
Prior to operating Marathon and Paragon, Aronin founded Ovation Pharmaceuticals LLC in 2000 and served as its chairman and CEO for nine years. On February 9, 2009, it was announced that H. Lundbeck A/S, a Danish pharmaceutical company, had purchased Ovation for $900 million.Chicago Mayor Rahm Emanuel appointed Aronin to the board of directors of World Business Chicago and co-chair of ChicagoNEXT. Aronin is also co-chair MATTER, a start-up center in Chicago for next-generation healthcare technology companies that opened in February 2015. He also serves on the board of trustees of Discover Financial Services and on the board of trustees of the Museum of Science and Industry.
On February 13, 2017, Aronin announced that Marathon would delay the launch of deflazacort (Emflaza) an "old drug" which is used to treat Duchenne muscular dystrophy, a rare disease that affects boys, amid controversy over the steep price Marathon was asking for the drug - $89,000-a-year. In Canada, the same drug could be purchased for around $1 per tablet. According to The Wall Street Journal, the price Marathon was proposing was "roughly 70 times" more than it would cost overseas. In a 2015 Chicago Tribune article, parents had expressed concerns that if deflazacort were approved in the United States, FDA guidelines seemed to suggest that parents would not "be able to order it from another country." They feared a "U.S. drug could be vastly more expensive than current international rates, leaving a question about insurance coverage." Senator Bernie Sanders and Rep. Elijah Cummings are investigating the price of the drug as part of a larger investigation about the cost of pharmaceuticals.
...
Wikipedia